Artios Pharma Limited

Artios

Artios develops DNA damage response small molecule therapeutics for patients with solid tumours and various cancer types.

Aprea Therapeutics

This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.

NeoPhore

This company develops small-molecule immuno-oncology medicines that inhibit DNA mismatch repair to stimulate immune responses against cancer for patients with solid tumours.

FoRx Therapeutics

The company develops oral small molecule drugs targeting DNA replication stress for patients with treatment-resistant cancers.

Aktis Oncology

This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.

Enara Bio

This company develops cancer immunotherapies targeting antigens derived from the dark genome for patients with solid tumours.

Enedra Therapeutics Ltd

This company develops precision medicines and biomarkers to treat advanced, genetically heterogeneous cancers for patients with drug-resistant tumours.

Abalos Therapeutics

This company develops arenavirus-based immuno-virotherapies to treat solid tumours and metastases for patients with cancer.